Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer

Sun, Yue; Shao, Chen; Li, Shan; Xu, Yan; Xu, Kai; Zhang, Ying; Huang, Hui; Wang, Mengzhao; Xu, Zuojun

doi:10.1111/ajco.13380

Cited by 12 publications

(25 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rashes were also commonly reported. Crackles on thorax auscultation manifested only in more advanced-grade CIP (23,86).…”

Section: Clinical Manifestationsmentioning

confidence: 97%

“…RT reportedly has a synergistic effect with immunotherapy (14,23). Intriguingly, RT itself could induce radiation pneumonitis in more than 30% of patients (109).…”

Section: Therapy Managementmentioning

confidence: 99%

“…The main clinical symptoms of CIP are relatively nonspecific and usually are similar to certain forms of ILD (23). CIP is characterized by fever, cough, chest pain, shortness of breath, dyspnea, fatigue, or respiratory failure (104).…”

Section: Clinical Manifestationsmentioning

confidence: 99%

“…Since before ICI therapies, pulmonary function has been compromised by tumor location and size in patients with NSCLC. In addition, preexisting lung comorbidities, such as chronic inflammatory respiratory diseases, interstitial fibrosis lung diseases, and radiation-induced pneumonitis (RIP), may cloud diagnostic accuracy because of the overlapping respiratory symptoms and signs (5,6,9,14,23). As a result, recognizing the unique clinical and imaging patterns of CIP is essential to facilitate expeditious diagnosis and optimized management principles.…”

Section: Introductionmentioning

confidence: 99%

“…Although previous studies have elucidated the incidence, potential mechanisms, diagnosis, risk factors, and management of CIP, they focused on variable focuses that were not comprehensive and deep enough (5,6,9,14,23,24). This review offers a summary of cases or case series concerning CIP in NSCLC, and it aims to identify the characteristics of typical patients who develop CIP.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

et al. 2021

View full text Add to dashboard Cite

Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy in multiple malignancies. Although it has achieved significant breakthrough in advanced non-small cell lung cancer patients, immune-related adverse events (irAEs) including checkpoint inhibitor pneumonitis (CIP), are widely reported. As the particularly worrisome and potentially lethal form of irAEs, CIP should be attached more importance. Especially in non-small cell lung cancer (NSCLC) patients, the features of CIP may be more complicated on account of the overlapping respiratory signs compromised by primary tumor following immunotherapy. Herein, we included the previous relevant reports and comprehensively summarized the characteristics, diagnosis, and management of CIP. We also discussed the future direction of optimal steroid therapeutic schedule for patients with CIP in NSCLC based on the current evidence.

show abstract

“…Rashes were also commonly reported. Crackles on thorax auscultation manifested only in more advanced-grade CIP (23,86).…”

Section: Clinical Manifestationsmentioning

confidence: 97%

“…RT reportedly has a synergistic effect with immunotherapy (14,23). Intriguingly, RT itself could induce radiation pneumonitis in more than 30% of patients (109).…”

Section: Therapy Managementmentioning

confidence: 99%

Section: Clinical Manifestationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

et al. 2021

View full text Add to dashboard Cite

show abstract

Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis

Chen,

Shi,

Fang

et al. 2024

Cancer Immunol Immunother

View full text Add to dashboard Cite

Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment

et al. 2023

Self Cite

View full text Add to dashboard Cite

This study aimed to explore the general characteristics and spectrum of hospitalized Chinese patients suffering from lung cancer with concomitant interstitial lung disease (LC-ILD). Furthermore, we compared their features before and after the period of immunotherapy for lung cancer. A retrospective analysis of the clinical characteristics of hospitalized LC patients with definite pathological diagnoses was performed from 2014 to 2021. ILD was defined after the review of chest CT imaging. There were 13,085 hospitalized LC patients. Among them, 509 patients (3.89%) had 551 cases of ILD. There were variable underlying causes of ILD, including idiopathic interstitial pneumonia (360 patients), LC treatment-associated ILD (134 cases), and connective tissue disease-associated ILD (55 patients). Although most LC-ILD patients were suffering from adenocarcinoma (204/40.1%), SCLC patients were prone to concomitant ILD (10.8% of all SCLC cases), followed by SCC (9.6% of all SCC cases). All but 10 LC-ILD patients received anti-LC treatment; however, only 39 (10.8%) LC-IIP patients received anti-ILD treatment. There were more LC-ILD patients in the 2018–2021 group than in the 2014–2017 group (5.16% vs. 2.03%, p < 0.001). The underlying causes of ILD were significantly different between the 2018–2021 group and the 2014–2017 group (p < 0.001). After adjusting for the number of hospitalized patients having the same LC pathological pattern, SCLC was determined to be the most likely to be concomitant with ILD, followed by SCC. Most LC-ILD patients were scheduled for anti-LC therapy; however, treatments for concomitant IIP were usually ignored. LC treatment-associated ILD should receive more attention than before.

show abstract

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer

Cited by 12 publications

References 50 publications

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis

Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment

Contact Info

Product

Resources

About